- Home
- LXEH vs ALXO Comparison
LXEH vs ALXO Comparison
Compare LXEH & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- ALXO
- Stock Information
- Founded
- LXEH 2001
- ALXO 2015
- Country
- LXEH China
- ALXO United States
- Employees
- LXEH N/A
- ALXO N/A
- Industry
- LXEH Other Consumer Services
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- ALXO Health Care
- Exchange
- LXEH Nasdaq
- ALXO Nasdaq
- Market Cap
- LXEH 25.1M
- ALXO 28.3M
- IPO Year
- LXEH 2020
- ALXO 2020
- Fundamental
- Price
- LXEH $2.01
- ALXO $0.49
- Analyst Decision
- LXEH
- ALXO Strong Buy
- Analyst Count
- LXEH 0
- ALXO 6
- Target Price
- LXEH N/A
- ALXO $3.30
- AVG Volume (30 Days)
- LXEH 343.6K
- ALXO 455.1K
- Earning Date
- LXEH 06-10-2025
- ALXO 05-08-2025
- Dividend Yield
- LXEH N/A
- ALXO N/A
- EPS Growth
- LXEH N/A
- ALXO N/A
- EPS
- LXEH N/A
- ALXO N/A
- Revenue
- LXEH $4,493,795.00
- ALXO N/A
- Revenue This Year
- LXEH N/A
- ALXO N/A
- Revenue Next Year
- LXEH N/A
- ALXO N/A
- P/E Ratio
- LXEH N/A
- ALXO N/A
- Revenue Growth
- LXEH N/A
- ALXO N/A
- 52 Week Low
- LXEH $1.53
- ALXO $0.41
- 52 Week High
- LXEH $50.08
- ALXO $11.23
- Technical
- Relative Strength Index (RSI)
- LXEH 34.36
- ALXO 48.82
- Support Level
- LXEH $1.90
- ALXO $0.44
- Resistance Level
- LXEH $2.35
- ALXO $0.48
- Average True Range (ATR)
- LXEH 0.38
- ALXO 0.04
- MACD
- LXEH 0.44
- ALXO 0.01
- Stochastic Oscillator
- LXEH 24.15
- ALXO 61.92
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.